According to MedPage Today (9/23, George), on Sept. 23, the FDA announced that “benzodiazepines will be required to have class-wide labeling changes to include warnings about risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions.” These “updates will be made to the boxed warning benzodiazepines already carry that cautions about risks associated with using the” medications “concurrently with certain opioids.”
Related Links:
— MedPage Today (requires login and subscription)